Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report released on Saturday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

Shares of Accelerate Diagnostics stock opened at $1.35 on Friday. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $4.07. The business’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $1.54. The company has a market capitalization of $33.81 million, a P/E ratio of -0.47 and a beta of 0.59.

Insider Transactions at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of Accelerate Diagnostics stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the transaction, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 43.60% of the company’s stock.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.